Logo image of MESO

MESOBLAST LTD- SPON ADR (MESO) Stock Fundamental Analysis

NASDAQ:MESO - Nasdaq - US5907174016 - ADR - Currency: USD

15.17  -0.09 (-0.59%)

After market: 15.17 0 (0%)

Fundamental Rating

2

Overall MESO gets a fundamental rating of 2 out of 10. We evaluated MESO against 553 industry peers in the Biotechnology industry. MESO may be in some trouble as it scores bad on both profitability and health. MESO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MESO has reported negative net income.
MESO had a negative operating cash flow in the past year.
MESO had negative earnings in each of the past 5 years.
MESO had a negative operating cash flow in each of the past 5 years.
MESO Yearly Net Income VS EBIT VS OCF VS FCFMESO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

MESO has a better Return On Assets (-13.46%) than 82.10% of its industry peers.
MESO's Return On Equity of -19.07% is amongst the best of the industry. MESO outperforms 85.90% of its industry peers.
Industry RankSector Rank
ROA -13.46%
ROE -19.07%
ROIC N/A
ROA(3y)-13.06%
ROA(5y)-12.61%
ROE(3y)-17.67%
ROE(5y)-16.84%
ROIC(3y)N/A
ROIC(5y)N/A
MESO Yearly ROA, ROE, ROICMESO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

MESO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MESO Yearly Profit, Operating, Gross MarginsMESO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

2

2. Health

2.1 Basic Checks

MESO does not have a ROIC to compare to the WACC, probably because it is not profitable.
MESO has more shares outstanding than it did 1 year ago.
MESO has more shares outstanding than it did 5 years ago.
MESO has a worse debt/assets ratio than last year.
MESO Yearly Shares OutstandingMESO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MESO Yearly Total Debt VS Total AssetsMESO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 3.97 indicates that MESO is not in any danger for bankruptcy at the moment.
MESO has a Altman-Z score of 3.97. This is in the better half of the industry: MESO outperforms 75.59% of its industry peers.
A Debt/Equity ratio of 0.23 indicates that MESO is not too dependend on debt financing.
MESO has a Debt to Equity ratio of 0.23. This is in the lower half of the industry: MESO underperforms 70.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 3.97
ROIC/WACCN/A
WACC8.95%
MESO Yearly LT Debt VS Equity VS FCFMESO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 0.96 indicates that MESO may have some problems paying its short term obligations.
MESO's Current ratio of 0.96 is on the low side compared to the rest of the industry. MESO is outperformed by 88.43% of its industry peers.
A Quick Ratio of 0.63 indicates that MESO may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.63, MESO is doing worse than 91.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.63
MESO Yearly Current Assets VS Current LiabilitesMESO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

MESO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.22%, which is quite good.
The Revenue for MESO has decreased by -21.32% in the past year. This is quite bad
MESO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.80% yearly.
EPS 1Y (TTM)15.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.95%
Revenue 1Y (TTM)-21.32%
Revenue growth 3Y-7.5%
Revenue growth 5Y-18.8%
Sales Q2Q%-6.85%

3.2 Future

Based on estimates for the next years, MESO will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.88% on average per year.
The Revenue is expected to grow by 148.07% on average over the next years. This is a very strong growth
EPS Next Y-1.85%
EPS Next 2Y19.75%
EPS Next 3Y26.38%
EPS Next 5Y18.88%
Revenue Next Year153.13%
Revenue Next 2Y223.74%
Revenue Next 3Y236.18%
Revenue Next 5Y148.07%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MESO Yearly Revenue VS EstimatesMESO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
MESO Yearly EPS VS EstimatesMESO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MESO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MESO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MESO Price Earnings VS Forward Price EarningsMESO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MESO Per share dataMESO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

MESO's earnings are expected to grow with 26.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.75%
EPS Next 3Y26.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MESO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MESOBLAST LTD- SPON ADR

NASDAQ:MESO (8/1/2025, 8:00:00 PM)

After market: 15.17 0 (0%)

15.17

-0.09 (-0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-29 2025-07-29/amc
Earnings (Next)N/A N/A
Inst Owners16.91%
Inst Owner Change-2.28%
Ins Owners18.01%
Ins Owner ChangeN/A
Market Cap1.93B
Analysts77.78
Price Target11.96 (-21.16%)
Short Float %2.97%
Short Ratio10.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.08%
PT rev (3m)0.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 326.43
P/FCF N/A
P/OCF N/A
P/B 4.18
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0.05
BVpS3.63
TBVpS-0.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.46%
ROE -19.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.06%
ROA(5y)-12.61%
ROE(3y)-17.67%
ROE(5y)-16.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 3.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.96
Quick Ratio 0.63
Altman-Z 3.97
F-Score3
WACC8.95%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.22%
Cap/Sales(5y)7.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.95%
EPS Next Y-1.85%
EPS Next 2Y19.75%
EPS Next 3Y26.38%
EPS Next 5Y18.88%
Revenue 1Y (TTM)-21.32%
Revenue growth 3Y-7.5%
Revenue growth 5Y-18.8%
Sales Q2Q%-6.85%
Revenue Next Year153.13%
Revenue Next 2Y223.74%
Revenue Next 3Y236.18%
Revenue Next 5Y148.07%
EBIT growth 1Y-6.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.97%
EBIT Next 3Y77.21%
EBIT Next 5YN/A
FCF growth 1Y29.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.22%
OCF growth 3YN/A
OCF growth 5YN/A